# RUBEX — FDA application ANDA062926

Informational only - not investment advice.

Application ANDA062926 · type ANDA · FDA status: approved · original approval 1989-04-13

Listed sponsor: BRISTOL MYERS SQUIBB · [BMY company profile](/company/BMY/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | RUBEX | DOXORUBICIN HYDROCHLORIDE | INJECTABLE | INJECTION | 10MG/VIAL | Discontinued | not listed | No |
| 002 | RUBEX | DOXORUBICIN HYDROCHLORIDE | INJECTABLE | INJECTION | 50MG/VIAL | Discontinued | not listed | No |
| 003 | RUBEX | DOXORUBICIN HYDROCHLORIDE | INJECTABLE | INJECTION | 100MG/VIAL | Discontinued | not listed | No |

## Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- DOXORUBICIN HYDROCHLORIDE · UNII not resolved · no lmmol compound match

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/BMY/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA062926. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.